Pay in 4 interest-free payments of $6.53 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
A long-term data study found that semaglutide users, on average, lost 10% of their total weight and maintained these results for 4 years (5)
UK eligibility follows NICE guidance: typically for type 2 diabetes with inadequate glycaemic control or obesity with BMI 35 kg/m (or lower thresholds for certain ethnic groups) plus weight-related comorbidities
Chemical modifications can improve stability, alter pharmacokinetics, or enhance target selectivity, potentially addressing traditional limitations of peptide drugs
To determine if peptides are working, its important to track both subjective and objective changes in your body
Clinical trial data for retatrutide, including Phase 2 results published in the New England Journal of Medicine (Jastreboff et al., 2023), identified gastrointestinal adverse events as the most common side effects reported by participants
Your GP needs a complete picture of your medication regimen, including over-the-counter products and supplements
